Trump’s ‘Great Healthcare Plan’ aims to cut costs, sparks doubt

NEW YORK, UNITED STATES — United States President Donald Trump rolled out what he called the “Great Healthcare Plan,” a sweeping framework aimed at lowering prescription drug prices and insurance premiums, but healthcare leaders say the proposal raises more questions than answers for hospitals, health systems, and clinics already navigating thin margins and policy uncertainty.

In a report from MedCity News, it was argued that the plan, released amid ongoing debate in Congress over the future of Affordable Care Act premium subsidies, proposes a mix of drug pricing reforms, insurance transparency mandates and changes to how federal subsidies are distributed. 

While the White House framed the initiative as a path to immediate relief for consumers, healthcare executives say the lack of operational detail makes it difficult to assess how providers would ultimately be affected.

Cost pressures and policy uncertainty

At the center of the plan is a call to codify Most-Favored-Nation drug pricing, an approach designed to align U.S. drug prices with those paid in comparable countries. 

For hospitals and clinics, which face rising pharmaceutical expenses, the idea could signal future relief — but only if it is implemented clearly and consistently.

“Everyone wants to see drug prices and premiums come down,” said Ari Hoffman, senior vice president and chief clinical officer at Collective Health. 

“The challenge is how you get there, and the plan released by the White House has almost no details on how,” Hoffman added. 

Hoffman warned that uncertainty itself can drive higher costs, noting that “insurance pricing is too sensitive to uncertainty, and when policies change in ways the market can’t predict, that risk ends up getting baked into premiums.”

For providers, higher premiums can translate into more uninsured or underinsured patients, increasing uncompensated care and financial strain, particularly for community hospitals and safety-net clinics.

Transparency rules and uneven impacts

The Great Healthcare Plan would also require insurers to publish coverage and rate comparisons in “plain English,” along with public disclosures of claims denial rates, overhead, profits, and average wait times for routine care. 

Although these mechanisms aim to benefit consumers, providers anticipate varying downstream effects on volume.

Dr. Drew Altman, president and CEO of KFF, said major policy questions remain unanswered. 

“We have been trying to analyze the Trump health ‘plan’ but I worry that unless Congress puts something real together we are analyzing air,” he said, adding that it is impossible to tell from the fact sheet whether protections for pre-existing conditions would remain.

Ahmed Elsayyad, president of Ostro, said the plan could produce limited gains in areas where patients can shop for care. 

“In the best case, it increases price sensitivity in the parts of healthcare that are actually shop-able,” he said, but added that much of healthcare spending is urgent and complex, limiting consumer choice. 

“Net: potential marginal improvements, but unlikely to be a structural cost reset without detailed funding, enforcement, and guardrails for lower-income and high-risk patients,” Elsayyad added.

Health insurers, represented by AHIP, struck a more receptive tone. 

“Health plans welcome ideas to bring down the unaffordable prices drugmakers charge Americans and to empower consumers to make the best health care decisions for themselves and their families,” said spokesperson Chris Bond.

For providers, the message is clear: until Congress fills in the gaps, the plan’s real impact on hospitals and clinics remains uncertain.